$INCY

Incyte Corp. (INCY) is advancing two cancer treatments, INCB161734 and INCA33890, into late-stage trials after early results showed promising responses in pancreatic and colorectal cancers. INCB161734, combined with chemotherapy, showed high response rates in pancreatic cancer, while INCA33890 demonstrated activity in colorectal cancer. The company plans Phase 3 trials with topline results expected in 2028 and 2029, respectively.

Incyte Corp. sued Granules India Ltd. for allegedly infringing five patents related to its blood cancer drug Jakafi XR. Incyte claims Granules filed an FDA application to sell a generic version before its patents expire. The case was filed in the US District Court for the Eastern District of Texas.

Incyte, a biopharmaceutical company, is using AI scientist Kosmos to speed up drug target reviews, completing assessments in less than a day. According to Incyte, Kosmos can produce in a morning what would take a scientist 3 months. The system aims to improve strategic considerations and portfolio fit. Incyte announced its collaboration with Edison in May. Pfizer has also partnered with Edison to use Kosmos, combining public and proprietary data.

Incyte secured an interim injunction in India against Melody Healthcare regarding its ruxolitinib patent, just 11 weeks before the patent's expiration. The Delhi High Court ruled in favor of interim protection due to the patent's remaining validity and lack of competing commercial launch. According to the court, this ruling highlights the availability of interim protection against threatened infringement before a rival's commercial launch.

Major U.S. indexes rallied on Wednesday, with the Dow up 3.0%, S&P 500 up 1.8%, and Nasdaq up 1.8%. Biotech stocks also rose, with the Nasdaq Biotechnology Index up 2.1%. Amgen reported $10.4B in Q3 revenue, Gilead raised full-year guidance, Vertex saw 12% revenue growth, Incyte increased sales guidance, and Merck narrowed its sales range. Shares of these companies rose between 2.6% and 4.4%.

Incyte (INCY) will present new data on its hematology portfolio at ASH 2026, including updates on INCA033989 for myelofibrosis and essential thrombocythemia, and latarcibart for von Willebrand disease. Over 30 abstracts will be shared, with an investor event scheduled for December 12, 2026.

Incyte will present new data on its experimental antibody INCA033989 for first-line myelofibrosis treatment at a December event. The company will also share preclinical findings for its next-generation mutCALR- and JAK2V617F-targeted compounds. Incyte's investor event is scheduled for December 12, 2026, where these results will be discussed.

A phase 3 study found that ruxolitinib cream was well tolerated and maintained disease control in children aged 2-11 with mild to moderate atopic dermatitis (AD) over 44 weeks. The study, funded by Incyte Corporation, showed 79.5% of children on 0.75% strength and 72.3% on 1.5% had clear or almost clear skin at week 52. Common side effects included upper respiratory tract infection and neutropenia. The authors suggest ruxolitinib cream as a potential corticosteroid-free treatment option for AD.

Bernstein kept Incyte at Market Perform, raising its price target to $108 from $104. This implies a 10.3% downside from the Oct 30 close of $120.39. Recent analyst price targets for Incyte range from $117 to $144.

Incyte (INCY) and Genmab (GMAB) will jointly fund a Phase 1/2 trial combining Incyte's KRAS G12D inhibitor (INCB161734) and Genmab's bispecific antibody (petosemtamab) with chemotherapy for metastatic colorectal cancer with KRAS G12D mutation. The trial aims to evaluate the combination's safety and efficacy, targeting a subtype with limited treatment options.